Philips fighting tooth and nail as Masimo patent tussle rumbles on
This article was originally published in Clinica
The latest development in a long drawn-out patent infringement wrangle between Philips and Masimo may have been in the latter’s favor but the fight is far from over, according to Philips.
You may also be interested in...
Market Intel: Medtronic, Philips, Masimo, And Others Keep Pulse Beating In Oximetry Patient Monitoring Market
Demand for reliable, accurate, high-quality pulse oximetry devices in and – increasingly – outside hospitals is driven by the rise of chronic diseases, a growing elderly population prone to asthma, heart disease, sleep apnea and chronic obstructive pulmonary disease, as well as the need to monitor oxygen levels in premature babies. According to a new report by Meddevicetracker, the global market for standalone, hospital-grade pulse oximetry devices and accessories will reach $1.9bn by 2021, a CAGR of 5.4% from 2016. In this feature, we'll take a closer look at the overall pulse oximetry market, the major players and which forces are driving – and stymying – its growth.
Minimally invasive glaucoma surgery specialist Glaukos saw its stock leap 40% in the wake of a worldwide recall by much bigger rival Alcon of its CyPass microstent.
Roland Diggelmann will end his decade-long career at Roche Diagnostics at the end of September. The business's head of EMEA Michael Heuer will take Diggelmann's place while the search is on for his replacement.